Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Dna X (SONM) over the last 3 years, with Q3 2025 value amounting to $42956.0.

  • Dna X's Gains from Sales and Divestitures fell 1037.58% to $42956.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $42956.0, marking a year-over-year decrease of 1037.58%. This contributed to the annual value of $57621.0 for FY2024, which is 9069.19% down from last year.
  • Latest data reveals that Dna X reported Gains from Sales and Divestitures of $42956.0 as of Q3 2025, which was down 1037.58% from $773960.0 recorded in Q2 2025.
  • Dna X's Gains from Sales and Divestitures' 5-year high stood at $773960.0 during Q2 2025, with a 5-year trough of $2149.0 in Q1 2025.
  • Over the past 3 years, Dna X's median Gains from Sales and Divestitures value was $47929.0 (recorded in 2024), while the average stood at $245271.4.
  • As far as peak fluctuations go, Dna X's Gains from Sales and Divestitures tumbled by 9208.3% in 2024, and later soared by 190793.88% in 2025.
  • Dna X's Gains from Sales and Divestitures (Quarter) stood at $619042.0 in 2023, then plummeted by 90.69% to $57621.0 in 2024, then fell by 25.45% to $42956.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $42956.0 for Q3 2025, versus $773960.0 for Q2 2025 and $2149.0 for Q1 2025.